FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
21 October 2024
21 October 2024
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.